China Nuokang Bio-Pharma, a leading provider of blood-clotting medication in China, raised $45 million by offering 5 million ADSs at $9.00, below the low end of the $10.00 to $12.00 proposed range. China Nuokang Bio-Pharma is expected to begin trading Thursday on the NASDAQ under the symbol NKBP. Jefferies acted as lead manager on the deal.
